{"product_id":"bmy-marketing-mix","title":"Bristol-Myers Squibb Company (BMY): Marketing Mix Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made late-2025 Marketing Mix Analysis of Bristol-Myers Squibb Company gives you a practical, research-based snapshot of how the company’s key medicines, including Eliquis, Opdivo, Revlimid, Breyanzi, Camzyos, Reblozyl, and Sotyktu, are positioned across hospitals, clinics, specialty pharmacies, and oncology infusion centers in the U.S. and international markets. You’ll see how physician detailing, congress presentations, label-expansion updates, investor messaging, and patient support shape demand, while premium branded pricing, payer negotiations, reimbursement dependence, and generic erosion on legacy brands affect growth and margins.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eBristol-Myers Squibb Company - Marketing Mix: Product\u003c\/h2\u003e\n\n\u003cp\u003eBristol-Myers Squibb Company’s product mix is anchored by \u003cstrong\u003eEliquis\u003c\/strong\u003e, \u003cstrong\u003eOpdivo\u003c\/strong\u003e, and \u003cstrong\u003eRevlimid\u003c\/strong\u003e, with growth products led by \u003cstrong\u003eBreyanzi\u003c\/strong\u003e, \u003cstrong\u003eCamzyos\u003c\/strong\u003e, \u003cstrong\u003eReblozyl\u003c\/strong\u003e, and \u003cstrong\u003eSotyktu\u003c\/strong\u003e. The pipeline has also been expanded through acquisitions of \u003cstrong\u003e$74.0 billion\u003c\/strong\u003e, \u003cstrong\u003e$4.8 billion\u003c\/strong\u003e, and \u003cstrong\u003e$14.0 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eMolecule or modality\u003c\/th\u003e\n\u003cth\u003eDosage form and strength\u003c\/th\u003e\n\u003cth\u003eCore product role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis\u003c\/td\u003e\n\u003ctd\u003eApixaban\u003c\/td\u003e\n\u003ctd\u003eTablets, \u003cstrong\u003e2.5 mg\u003c\/strong\u003e and \u003cstrong\u003e5 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eOral anticoagulant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpdivo\u003c\/td\u003e\n\u003ctd\u003eNivolumab\u003c\/td\u003e\n\u003ctd\u003eIV solution for infusion, \u003cstrong\u003e10 mg\/mL\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eOncology immunotherapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevlimid\u003c\/td\u003e\n\u003ctd\u003eLenalidomide\u003c\/td\u003e\n\u003ctd\u003eCapsules, \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e15 mg\u003c\/strong\u003e, \u003cstrong\u003e20 mg\u003c\/strong\u003e, \u003cstrong\u003e25 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHematology-oncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreyanzi\u003c\/td\u003e\n\u003ctd\u003eLisocabtagene maraleucel\u003c\/td\u003e\n\u003ctd\u003eCell suspension for infusion, \u003cstrong\u003e100 million\u003c\/strong\u003e CAR-positive viable T cells\u003c\/td\u003e\n\u003ctd\u003eCell therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCamzyos\u003c\/td\u003e\n\u003ctd\u003eMavacamten\u003c\/td\u003e\n\u003ctd\u003eCapsules, \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e15 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCardiomyopathy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReblozyl\u003c\/td\u003e\n\u003ctd\u003eLuspatercept-aamt\u003c\/td\u003e\n\u003ctd\u003eVials, \u003cstrong\u003e25 mg\u003c\/strong\u003e and \u003cstrong\u003e75 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAnemia in hematology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSotyktu\u003c\/td\u003e\n\u003ctd\u003eDeucravacitinib\u003c\/td\u003e\n\u003ctd\u003eTablet, \u003cstrong\u003e6 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eImmunology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eEliquis\u003c\/strong\u003e is the clearest volume product in the portfolio. It comes in \u003cstrong\u003e2\u003c\/strong\u003e tablet strengths and is an oral, twice-daily medicine. Its U.S. label covers \u003cstrong\u003e4\u003c\/strong\u003e main uses: stroke prevention in nonvalvular atrial fibrillation, deep vein thrombosis prophylaxis after hip or knee replacement, treatment of deep vein thrombosis and pulmonary embolism, and reduction in the risk of recurrent DVT and PE.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOpdivo\u003c\/strong\u003e is the main oncology immunotherapy platform. It is an intravenous product at \u003cstrong\u003e10 mg\/mL\u003c\/strong\u003e, which makes it a clinic-administered medicine rather than a retail pharmacy product. That matters because dosing, infusion capacity, and reimbursement are tied to hospital and oncology practice settings.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRevlimid\u003c\/strong\u003e remains one of the company’s most important hematology assets, but its product role has changed because U.S. generic entry began in \u003cstrong\u003e2022\u003c\/strong\u003e. The product still matters because it established scale in multiple myeloma and related blood cancers, but it no longer has the same exclusivity profile it once had.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBreyanzi\u003c\/strong\u003e is a personalized cell therapy with a \u003cstrong\u003e100 million\u003c\/strong\u003e CAR-positive viable T-cell dose.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCamzyos\u003c\/strong\u003e is sold in \u003cstrong\u003e4\u003c\/strong\u003e capsule strengths: \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, and \u003cstrong\u003e15 mg\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReblozyl\u003c\/strong\u003e uses \u003cstrong\u003e2\u003c\/strong\u003e vial sizes: \u003cstrong\u003e25 mg\u003c\/strong\u003e and \u003cstrong\u003e75 mg\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSotyktu\u003c\/strong\u003e is a single-strength product at \u003cstrong\u003e6 mg\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBreyanzi\u003c\/strong\u003e, \u003cstrong\u003eCamzyos\u003c\/strong\u003e, and \u003cstrong\u003eReblozyl\u003c\/strong\u003e sit in the growth layer of the portfolio. Breyanzi is a CAR-T therapy, so one patient receives one customized product. Camzyos is an oral cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy. Reblozyl is a subcutaneous biologic used in anemia settings, which gives Bristol-Myers Squibb Company a broader hematology franchise beyond classic oncology.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSotyktu\u003c\/strong\u003e is the immunology product in the mix. It is a \u003cstrong\u003e6 mg\u003c\/strong\u003e once-daily oral tablet and gives Bristol-Myers Squibb Company exposure outside oncology and cardiovascular disease. As a single-strength oral product, it has a simpler packaging profile than infused biologics or individualized cell therapy.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eTransaction\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eProduct relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCelgene acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$74.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAdded Revlimid and expanded hematology-oncology scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMirati Therapeutics acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpanded oncology pipeline with adagrasib\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKaruna Therapeutics acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpanded neuroscience pipeline with xanomeline-trospium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThose transactions matter because Bristol-Myers Squibb Company uses in-licensing and M\u0026amp;A to replace revenue that falls away as products lose exclusivity. The product mix is not just a list of medicines; it is a portfolio built from oral tablets, capsules, infused antibodies, autologous cell therapy, and acquired late-stage pipeline assets.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eBristol-Myers Squibb Company - Marketing Mix: Place\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in revenues in 2023 came from a prescription-drug model, so distribution depends on payer access, wholesaler inventory, specialty pharmacy placement, and administration sites rather than consumer retail shelves.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal prescription-drug commercialization\u003c\/strong\u003e runs through a regulated supply chain. Prescription medicines move from manufacturer to wholesale distributor, specialty pharmacy, hospital, clinic, or infusion center before they reach the patient. For a company with a \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e revenue base, place strategy is a commercial control point, because a product with formulary access but weak channel placement can still miss prescriptions.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePlace channel\u003c\/th\u003e\n\u003cth\u003eReal-life number or amount\u003c\/th\u003e\n\u003cth\u003eChannel role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompanywide revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023 full-year prescription-drug scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect retail consumer channel\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRx-only model, not a consumer packaged-goods model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology site of care\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHospital outpatient departments and freestanding infusion centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic reach\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 100 countries\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCommercial availability across U.S. and international markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEligible patient out-of-pocket cost\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFree-medicine access can apply under assistance programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospitals, clinics, and specialty pharmacies\u003c\/strong\u003e are the main dispensing points for many Bristol-Myers Squibb Company therapies. Specialty pharmacies matter because they manage prior authorization, benefit verification, shipment timing, and refill coordination. Hospitals and clinics matter because they handle infused and clinic-administered medicines that cannot be treated like standard retail prescriptions. The commercial value of this channel mix is that it keeps treatment where the prescriber and the payer can see it, which raises fill rates and reduces abandonment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology and infusion-center channels\u003c\/strong\u003e are especially important because infused cancer therapies are tied to scheduled appointments. That makes place a site-of-care issue, not just a pharmacy issue. The relevant physical locations are hospital outpatient departments and freestanding infusion centers, which create a controlled environment for administration, monitoring, and reimbursement review. In practice, access depends on the facility’s stocking, the payer’s coverage decision, and the patient’s appointment window.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospital outpatient departments\u003c\/li\u003e\n\u003cli\u003eFreestanding infusion centers\u003c\/li\u003e\n\u003cli\u003eOncology clinics\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacies\u003c\/li\u003e\n\u003cli\u003eWholesale distributors\u003c\/li\u003e\n\u003cli\u003eInstitutional accounts\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroad U.S. and international reach\u003c\/strong\u003e means the same prescription product can sit in different channels across markets. In the U.S., large-scale payer systems shape where the drug is dispensed and which site of care is used. Outside the U.S., local pricing, import rules, reimbursement systems, and country-level tenders affect whether a medicine is stocked in a public hospital, private clinic, or specialty pharmacy network. The practical place problem is availability at the right location, not just regulatory approval.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAccess programs in low-income markets\u003c\/strong\u003e are the final layer of place strategy. Where patients cannot afford standard pricing, eligible support can reduce out-of-pocket cost to \u003cstrong\u003e$0\u003c\/strong\u003e. For prescription medicines, this is not only a pricing issue; it is a distribution issue, because patients still need a dispensing route, documentation, and delivery channel that works in lower-income settings. In those markets, the useful channel is often a patient-assistance pathway, a nonprofit distribution partner, or a local institutional buyer rather than a retail pharmacy.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eBristol-Myers Squibb Company - Marketing Mix: Promotion\u003c\/h2\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s promotion is built around a \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e 2023 net sales base and a specialty-drug model that depends on physician education, clinical data, investor messaging, and patient access support. The company’s promotion is strongest in oncology, hematology, cardiovascular disease, immunology, and neuroscience.\u003c\/p\u003e\n\n\u003ch3\u003ePhysician-focused scientific detailing\u003c\/h3\u003e\n\u003cp\u003ePromotion to physicians is centered on specialty sales teams, medical affairs, and peer-to-peer education. That matters because prescription decisions in oncology and other specialty areas depend on trial results, dosing, safety, biomarker testing, and reimbursement rules. This is especially relevant for products such as Opdivo, Yervoy, Eliquis, Reblozyl, Breyanzi, Camzyos, Sotyktu, and Cobenfy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-acuity therapies need repeated one-to-one education.\u003c\/li\u003e\n\u003cli\u003ePhysicians respond to clinical endpoints, label language, and patient selection.\u003c\/li\u003e\n\u003cli\u003eMedical-science communication matters more than consumer advertising for prescription drugs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCongress and clinical-data presentations\u003c\/h3\u003e\n\u003cp\u003eMajor congresses are a core promotion channel because they turn trial data into public, peer-reviewed discussion. Bristol-Myers Squibb Company uses meetings such as ASCO, ASH, ESMO, AHA, and ACC to keep its products visible with specialists, hospital buyers, and guideline writers.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePromotion channel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life marker\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness impact\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientific congresses\u003c\/td\u003e\n\u003ctd\u003eASCO, ASH, ESMO, AHA, ACC\u003c\/td\u003e\n\u003ctd\u003eSupports physician adoption and keeps product data current\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestor communication\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e 2023 net sales\u003c\/td\u003e\n\u003ctd\u003eShows the scale behind pipeline promotion and lifecycle management\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch messaging\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eSeptember 26, 2024\u003c\/strong\u003e FDA approval of Cobenfy\u003c\/td\u003e\n\u003ctd\u003eCreates a new psychiatry promotion story\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess support\u003c\/td\u003e\n\u003ctd\u003eBenefits verification, prior authorization, copay support, patient assistance\u003c\/td\u003e\n\u003ctd\u003eReduces delays and abandonment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRegulatory label-expansion announcements\u003c\/h3\u003e\n\u003cp\u003eLabel-expansion announcements are a promotion tool because they widen the eligible patient pool and give sales teams a fresh message. Bristol-Myers Squibb Company uses FDA approval dates, new indications, and safety updates to re-engage physicians and payers. The \u003cstrong\u003eSeptember 26, 2024\u003c\/strong\u003e FDA approval of Cobenfy is a clear example of how a regulatory event becomes a launch and promotion event at the same time.\u003c\/p\u003e\n\n\u003ch3\u003eInvestor communications on pipeline growth\u003c\/h3\u003e\n\u003cp\u003eInvestor promotion focuses on how current sales fund future growth. The company’s \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in 2023 net sales is the key anchor for this message, because it supports R\u0026amp;D, launch preparation, and clinical-data generation. The investor story is built around new approvals, label expansions, and pipeline readouts that can offset loss of exclusivity in older products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly earnings calls\u003c\/li\u003e\n\u003cli\u003eInvestor days\u003c\/li\u003e\n\u003cli\u003eConference presentations\u003c\/li\u003e\n\u003cli\u003ePipeline updates tied to clinical milestones\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003ePatient access and support programs\u003c\/h3\u003e\n\u003cp\u003ePatient promotion is mostly access support, not advertising. It usually includes coverage checks, prior authorization help, reimbursement navigation, and financial assistance for eligible patients. This matters because even when physicians want to prescribe, coverage friction can delay the start of therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBenefits verification\u003c\/li\u003e\n\u003cli\u003ePrior authorization support\u003c\/li\u003e\n\u003cli\u003eCopay support\u003c\/li\u003e\n\u003cli\u003ePatient assistance for eligible uninsured or underinsured patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eBristol-Myers Squibb Company - Marketing Mix: Price\u003c\/h2\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s pricing power sits in a small set of protected branded drugs. In 2023, net sales were \u003cstrong\u003e$45.0B\u003c\/strong\u003e, with Eliquis at \u003cstrong\u003e$12.2B\u003c\/strong\u003e, Opdivo at \u003cstrong\u003e$9.0B\u003c\/strong\u003e, and Revlimid at \u003cstrong\u003e$5.6B\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePremium branded-drug pricing\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe top 3 products generated \u003cstrong\u003e$26.8B\u003c\/strong\u003e, or \u003cstrong\u003e59.6%\u003c\/strong\u003e of 2023 net sales. Eliquis represented \u003cstrong\u003e27.1%\u003c\/strong\u003e of net sales, Opdivo represented \u003cstrong\u003e20.0%\u003c\/strong\u003e, and Revlimid represented \u003cstrong\u003e12.4%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eShare of 2023 net sales\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis\u003c\/td\u003e\n\u003ctd\u003e$12.2B\u003c\/td\u003e\n\u003ctd\u003e27.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpdivo\u003c\/td\u003e\n\u003ctd\u003e$9.0B\u003c\/td\u003e\n\u003ctd\u003e20.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevlimid\u003c\/td\u003e\n\u003ctd\u003e$5.6B\u003c\/td\u003e\n\u003ctd\u003e12.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 3 total\u003c\/td\u003e\n\u003ctd\u003e$26.8B\u003c\/td\u003e\n\u003ctd\u003e59.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther products\u003c\/td\u003e\n\u003ctd\u003e$18.2B\u003c\/td\u003e\n\u003ctd\u003e40.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMarket access and payer negotiations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn \u003cstrong\u003e2025\u003c\/strong\u003e, the Medicare Part D annual out-of-pocket cap is \u003cstrong\u003e$2,000\u003c\/strong\u003e. The first Medicare drug price negotiation cycle covered \u003cstrong\u003e10\u003c\/strong\u003e drugs, with negotiated prices effective in \u003cstrong\u003e2026\u003c\/strong\u003e. Eliquis was one of the selected drugs.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2,000\u003c\/strong\u003e Medicare Part D annual out-of-pocket cap in \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e drugs in the first Medicare negotiation cycle\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2026\u003c\/strong\u003e effective date for negotiated prices\u003c\/li\u003e\n\u003cli\u003eEliquis included in the first negotiation cycle\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialty-drug reimbursement dependence\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOpdivo at \u003cstrong\u003e$9.0B\u003c\/strong\u003e and Eliquis at \u003cstrong\u003e$12.2B\u003c\/strong\u003e show how much Bristol-Myers Squibb Company depends on reimbursement decisions, formulary placement, and payer rebates. A small change in net price on a multi-billion-dollar specialty product has a much larger effect than the same change on a smaller product.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGeneric erosion on legacy brands\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRevlimid lost U.S. exclusivity in \u003cstrong\u003e2022\u003c\/strong\u003e. Its 2023 net sales of \u003cstrong\u003e$5.6B\u003c\/strong\u003e show the scale of post-exclusivity price pressure on legacy brands.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eProduct mix drives margin and price pressure\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe gap between \u003cstrong\u003e$26.8B\u003c\/strong\u003e from the top 3 products and \u003cstrong\u003e$18.2B\u003c\/strong\u003e from the rest shows how much Bristol-Myers Squibb Company’s realized pricing depends on product mix. A heavier mix of protected brands supports higher net pricing; a heavier mix of legacy brands increases discounting pressure.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44602202620053,"sku":"bmy-marketing-mix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/bmy-marketing-mix.png?v=1740155292","url":"https:\/\/dcf-model.com\/es\/products\/bmy-marketing-mix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}